Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formation
8.4
来源：
Nature
关键字：
computational pathology
发布时间：
2025-10-04 03:42
摘要：
Anle138b is a small molecule candidate that binds to lipidic Aβ₄₀ fibrils, significantly inhibiting their formation by approximately 75%. This study employs high-resolution techniques such as cryo-electron microscopy and NMR spectroscopy to elucidate the binding mechanisms at the atomic level. Anle138b has completed Phase I clinical trials and is currently in Phase II trials for multiple system atrophy, highlighting its potential as a therapeutic agent for Alzheimer's disease.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
0.8分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.4分
technical_barrier_competition
0.7分
关键证据
Anle138b reduces fibril formation by approximately 75%.
The study uses advanced techniques like cryo-EM and NMR to analyze binding interactions.
Anle138b has shown disease-modifying effects in various neurodegenerative models.
真实性检查
否
AI评分总结
Anle138b is a small molecule candidate that binds to lipidic Aβ₄₀ fibrils, significantly inhibiting their formation by approximately 75%. This study employs high-resolution techniques such as cryo-electron microscopy and NMR spectroscopy to elucidate the binding mechanisms at the atomic level. Anle138b has completed Phase I clinical trials and is currently in Phase II trials for multiple system atrophy, highlighting its potential as a therapeutic agent for Alzheimer's disease.